Aida Pharmaceuticals (AIDA)

[PaperProphet]

News today. Aida receives an award and associated monies of $164,982.47 from the Science and Technology Department of Zhejiang Province for thier anti-cancer drug, Rh-Apo2L.

I suspect what shareholders really want to hear are the statistics and results of the phase II trials. I wasn't able to find the results of the phase I trials either. For phase II, the only thing they say is "strong efficacy" but they don't give any meaningful details. Saying "strong efficacy" is a subjective opinion. Most people would rather invest in facts and not in adjectives.

---"Phase 2 testing results thus far have shown strong efficacy in treating lung cancer (non-small cell), non-Hodgkins lymphoma, stomach cancer, pancreatic cancer and kidney cancer."---